This study focuses on Piriformis Muscle Syndrome, a condition where the piriformis muscle in the buttock region causes pain and discomfort along the sciatic nerve. The research evaluates the effectiveness of XEOMIN, which contains botulinum toxin, compared to placebo in treating this condition. The medication is specifically designed for patients who have not found relief through conventional treatments like physiotherapy, muscle relaxants, or pain medications.

The purpose of the study is to determine if a single injection of botulinum toxin can reduce sciatic pain in people with Piriformis Muscle Syndrome. During the study, participants will receive one injection of either XEOMIN or placebo into the affected muscle. The injection will be guided by ultrasound or computed tomography to ensure accurate placement. The treatment’s effects will be monitored over six months, with particular attention to pain levels after six weeks.

The medication being tested, XEOMIN, is administered as a solution for injection into the muscle. Each dose contains up to 200 units of botulinum toxin. Some patients may receive a second injection after 12 weeks if needed. Throughout the study, participants will be asked to report their pain levels and overall quality of life through various assessment tools.